(Press-News.org) April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.
Among GT-3 patients, SVR12 rates were highest in those receiving SOF+PEG/RBV for 12 weeks (93%) as compared to SOF+RBV for 24 (84%, p = 0.008) or 16 weeks (71%, p END
Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients
Results from the ground-breaking new BOSON study
2015-04-25
ELSE PRESS RELEASES FROM THIS DATE:
Alcohol use disorders - stronger predictor of mortality than chronic hepatitis C virus infection
2015-04-25
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.
The study found that chronic HCV infection has a limited impact on mortality, unless the patient also has other severe comorbidities, such as HIV infection, cancer or chronic kidney disease. In contrast, those with AUDs are at significant risk of death with a higher ...
Sofosbuvir/daclatasvir combination effective treatment for difficult-to-treat hep C patients
2015-04-25
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.
Overall, the sustained virologic response rate at 4 weeks (SVR4) for SOF/DCV was 81.6% after 12 weeks of treatment and 93.9% ...
DCV, SOF & RBV comb. effective/tolerated in HCV with adv, cirrhosis / post-transplant recurrence
2015-04-25
April 25, 2015, Vienna , Austria: Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. Sustained virologic response rates at 12 weeks (SVR12) were >90% in patients with Child-Pugh class A or B cirrhosis but lower in Child-Pugh class C. SVR12 was achieved by 94% of liver transplant recipients with HCV recurrence.
ALLY-1 ...
Drinking just 1 or 2 alcoholic drinks a day linked to liver disease
2015-04-25
April 25, 2015, Vienna, Austria: According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver CongressTM 2015 has shown the significant influence of daily drinking on this disease burden. New data shows that the cirrhosis burden caused by alcohol increased by 11.13% when moving from the moderate to heavy daily drinking (up to one drink/day for women; two drinks/day for men) classification (p END ...
Prelim. safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patients
2015-04-25
April 25, 2015, Vienna, Austria: Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study.
In the study, treatment naïve non-cirrhotic adults ...
Researchers highlight need for better evidence to guide EU efforts to increase hep B+C testing
2015-04-25
April 25, 2015, Vienna, Austria: The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver CongressTM 2015.
The systematic review concluded that the current evidence base on hepatitis B and C testing appears to be lacking in many European countries. At present it is informed primarily by published articles and conference abstracts from just 6 out of 53 member countries of ...
Use of pocket-sized ultrasound device reduces need for further testing in clinical settings
2015-04-25
April 25, 2015, Vienna, Austria: Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.
The study evaluated the effectiveness of the PUD when testing for the following conditions: biliary-duct dilation, gallstones, ascites, splenomegaly, pleural effusion, pericardial effusion, urinary retention, urinary stones, abdominal mass and aortic aneurysm.
PUDs offer a comparable performance ...
Hepatitis C screening essential to help catch patients with advanced liver fibrosis
2015-04-25
April 25, 2015, Vienna, Austria: Study results presented today at The International Liver Congress™ 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.
Most individuals with HCV remain asymptomatic, which makes the diagnosis difficult. The study authors used the hypothesis that individuals whose HCV is not diagnosed are less likely to have advanced fibrosis than those who have been diagnosed. They then compared liver fibrosis between respondents of the ...
Combined brachytherapy techniques should be 'benchmark' for cervical cancer treatment
2015-04-25
Barcelona, Spain: The first large international study to investigate the late side-effects of a combination of two forms of brachytherapy to treat cervical cancer has shown that the technique successfully delivers higher radiation doses to the tumour without an increase in treatment-related problems afterwards.
Brachytherapy is a type of internal radiotherapy that involves putting a radioactive source close to, or in the tumour. It is often performed after a CT or MRI scan has pinpointed the exact position of the cancer, so that the radiation treatment can be targeted ...
Mental disorders don't predict future violence
2015-04-25
Depression is not linked to violence among males
Some delinquent youth with current psychiatric illness may be violent
Providing treatment could reduce violence
CHICAGO --- Most psychiatric disorders - including depression -- do not predict future violent behavior, according to new Northwestern Medicine longitudinal study of delinquent youth. The only exception is substance abuse and dependence.
"Our findings are relevant to the recent tragic plane crash in the French Alps. Our findings show that no one could have predicted that the pilot - who apparently ...
LAST 30 PRESS RELEASES:
In global collaboration, IU scientists unlock secrets to the building blocks of the universe
Young adults fear mass shootings but don’t necessarily support gun control
How unlocking ‘sticky’ chemistry may lead to better, cleaner fuels
Cutting balloon treatment prior to stent placement comparable to intravascular lithotripsy for patients with calcified coronary artery disease
Novel sirolimus-eluting balloon appears noninferior to conventional therapies for treatment of in-stent restenosis
Nearly half of US workers don’t know work experience could count toward a degree, according to University of Phoenix survey
Super-high-pressure non-compliant balloons for treatment of calcified coronary lesions noninferior to intravascular lithotripsy
Saudi Native Dr. Hani K. Najm named next vice president of the American College of Cardiology
Getting steps in one long walk a day cuts risk of death and CVD better than multiple short walks
The way you walk: 10–15 minute bouts of walking better for your cardiovascular health than shorter strolls
Beyond electronics: harnessing light for faster computing
Researchers find possible cause for increasing polarization
From soft to solid: How a coral stiffens its skeleton on demand
New software tool MARTi fast-tracks identification and response to microbial threats
Rare brain cell may hold the key to preventing schizophrenia symptoms
A new tool to find hidden ‘zombie cells’
New Cleveland Clinic research finds up to 5% of Americans carry genetic mutations associated with cancer risk
Once tadpoles lose lungs, they never get them back
Small group of users drive invasive species awareness on social media
One bad safety review can tank an Airbnb booking — Even among thousands of positive ones, new study finds
Text-based system speeds up hospital discharges to long-term care
California schools are losing tree canopy
How people learn computer programming
Exploring a mechanism of psychedelics
Scientists can now explore mechanisms behind attachment issues
Researchers watched students’ brains as they learned to program
An AI-powered lifestyle intervention vs human coaching in the diabetes prevention program
AI-powered diabetes prevention program shows similar benefits to those led by people
New study may transform diagnosis of Britain’s number one cancer
Stillbirths in the United States
[Press-News.org] Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patientsResults from the ground-breaking new BOSON study